#5 - Immunomedics, Inc. (NASDAQ:IMMU)
Immunomedics, Inc. (NASDAQ: IMMU) - It’s never a good sign when a company has to “rob from Peter to pay Paul”, but that’s the situation facing Immunomedics. If you don’t look too closely, things might look pretty good. Sales of LeukoScan, their oncology diagnostics product, are robust. And it has another product, Sacituzumab Govitecan, considered its flagship product in Phase 2 trials. The company is also pushing forward with a product currently in Phase 3 testing called Epratuzumab. All of this sounds great until you look at how the company is funding its future projects. They have already announced plans to sell the rights its LeukoScan franchise because they need cash to fund the other projects in their pipeline. They have also sold the royalty rights to Sacituzumab Govitecan to Royalty Pharma. All of this is signaling what the company already knows, they are burning cash, and are headed for bankruptcy or some sort of partnership.
About Immunomedics
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States.
Read More - Current Price
- $87.86
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
